Key result
Microvolt T-wave alternans is an emerging prognostic tool for risk stratification to guide prophylactic implantable cardioverter-defibrillator therapy in patients with cardiomyopathy.
Why the study?
Does microvolt T-wave alternans measurement predict sudden cardiac death in patients with cardiomyopathy?
Does microvolt T-wave alternans measurement predict sudden cardiac death in patients with cardiomyopathy?
Microvolt T-wave alternans is an emerging non-invasive tool that may improve sudden cardiac death risk stratification in cardiomyopathy patients beyond ejection fraction.
May refine SCD risk stratification in cardiomyopathy; leaves open need for prospective validation before guiding ICD therapy.
PURPOSE OF REVIEW: Sudden cardiac death remains a major cause of mortality among patients with cardiomyopathy and implantable cardioverter-defibrillator therapy has been shown to improve survival in these patients. Effective use of prophylactic implantable cardioverter-defibrillator therapy requires accurate risk stratification beyond assessment of ejection fraction, however. Repolarization alternans is a harbinger of ventricular arrhythmias and its measurement from body-surface recordings, also known as microvolt T-wave alternans, is emerging as an effective prognostic tool in these patients based on recent clinical trials. RECENT FINDINGS: We review the pathogenesis and determinants of repolarization alternans. The current techniques for measuring T-wave alternans from the body surface are compared, including the spectral and modified moving average methods. Recent clinical trials evaluating the prognostic utility of T-wave alternans in patients with ischemic and nonischemic cardiomyopathy and no prior arrhythmic events are summarized. The findings of these studies are discussed in the context of implantable cardioverter-defibrillator prophylaxis. Body-surface T-wave alternans is an evolving technique and its limitations are presented along with approaches to improve its predictive accuracy. SUMMARY: Risk stratification with T-wave alternans has the potential to guide prophylactic implantable cardioverter-defibrillator therapy in a growing population of patients with cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Chauhan et al. (2006) conducted a review in Cardiomyopathy. Microvolt T-wave alternans was evaluated on Sudden cardiac death. Microvolt T-wave alternans is an emerging prognostic tool for risk stratification to guide prophylactic implantable cardioverter-defibrillator therapy in patients with cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: